What is the recommended management of proteinuria in a patient with an estimated glomerular filtration rate of 18 mL/min/1.73 m²?

Management of Proteinuria with eGFR 18 mL/min/1.73 m²

Continue ACE inhibitor or ARB therapy at the current dose unless there is symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or worsening uremic symptoms. At an eGFR of 18 mL/min/1.73 m², you are managing advanced CKD (Stage 4-5), and the primary goal is to slow progression while preparing for kidney replacement therapy.

Core Therapeutic Strategy

RAS Inhibition (First-Line)

• Maintain ACEi or ARB therapy even at this low eGFR level 1
• The KDIGO 2024 guidelines explicitly state to continue RAS inhibition when eGFR falls below 30 mL/min/1.73 m² 1
• Only consider dose reduction or discontinuation if:
  • Symptomatic hypotension occurs
  • Hyperkalemia remains uncontrolled despite potassium-lowering interventions
  • Uremic symptoms worsen (eGFR <15 mL/min/1.73 m²) 1

Critical caveat: If creatinine rises >30% within 4 weeks of any dose adjustment, continue the medication at the current dose rather than increasing 1. Manage hyperkalemia with dietary potassium restriction, diuretics, or potassium binders rather than stopping the RASi 1.

SGLT2 Inhibitor Consideration

Do NOT initiate an SGLT2i at eGFR 18 mL/min/1.73 m² - the threshold for initiation is eGFR ≥20 mL/min/1.73 m² 1

However, if the patient is already on an SGLT2i that was started when eGFR was ≥20, continue it even though eGFR has now fallen below 20 1. The reversible eGFR dip with SGLT2i is not an indication to stop therapy 1.

Mineralocorticoid Receptor Antagonist

Nonsteroidal MRA (finerenone) is contraindicated at eGFR 18 mL/min/1.73 m² - these agents require eGFR >25 mL/min/1.73 m² for initiation 1

Proteinuria-Specific Management Algorithm

Quantify the Proteinuria Level

The degree of proteinuria determines urgency and prognosis:

• UACR ≥700 mg/g: Extremely high risk - expect eGFR decline of ~5.5 mL/min/1.73 m² per year and 5.8-fold increased risk of cardiorenal hospitalization 2
• UACR 200-700 mg/g: High risk - warrants maximal medical therapy
• UACR <200 mg/g: Lower risk but still requires RASi therapy

Dietary Protein Restriction

• Target 0.6-0.8 g/kg/day protein intake at this eGFR level 3
• Ensure at least 50% is high-biologic-value protein
• Maintain energy intake of 30-35 kcal/kg/day to prevent protein-energy wasting 3
• This can reduce proteinuria and help defer dialysis initiation 3

Monitoring Parameters

Frequency

• Serum creatinine and potassium: Every 2-4 weeks initially, then monthly once stable
• Blood pressure: Every visit, target <130/80 mmHg in most patients
• UACR: Every 3 months to assess treatment response

Red Flags Requiring RASi Adjustment

• Potassium >5.5 mmol/L despite management
• Creatinine increase >30% from baseline
• Symptomatic orthostatic hypotension
• Progressive uremic symptoms (nausea, anorexia, pruritus)

Practical Pitfalls to Avoid

1. Don't reflexively stop RASi when eGFR declines - this is expected in advanced CKD and the long-term kidney protection outweighs short-term eGFR changes 1

2. Don't use dual RASi therapy (ACEi + ARB combination) - this increases adverse events without additional benefit 4

3. Don't delay nephrology referral - at eGFR 18, the patient needs kidney replacement therapy planning regardless of proteinuria management

4. Don't start SGLT2i at this eGFR - you've missed the window for initiation, though continuation is acceptable if already prescribed 1

Preparation for Kidney Failure

With eGFR 18 and proteinuria, projected time to kidney failure (eGFR <10) may be 3-6 years depending on proteinuria severity 5. Simultaneously initiate:

• Vascular access planning (fistula creation)
• Transplant evaluation if appropriate
• Patient education on dialysis modalities
• Sick day medication management protocols 6